Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $58 to $52.
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $68 t...
Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $57 to $47.
Conmed (NYSE:CNMD) narrows FY2025 Adj EPS guidance from $4.40-$4.55 to $4.48-$4.53 vs $4.47 analyst estimate. Narrows FY2025 sa...
Conmed (NYSE:CNMD) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $1.05 by 2.66 pe...
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $80 t...
Conmed (NYSE:CNMD) lowers FY2025 Adj EPS guidance from $4.45-$4.60 to $4.40-$4.55 vs $4.39 analyst estimate. Raises FY2025 sale...
Conmed (NYSE:CNMD) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.12 by 2.4 per...
